There is a report indicating PEPCK and G6Pase mRNA levels in liver biopsy samples from NASH patients to be higher than in the normal liver [15], while G6Pase mRNA expression was reported to be lower in liver biopsy samples from NAFLD patients [16]. This evidence concerns the gene PCK2 and metabolic dysfunction-associated steatotic liver disease.